Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting GlobeNewswire November 03, 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new […]